Neurocrine Biosciences, Inc. (NBIX)
138.38
+1.01
(+0.74%)
USD |
NASDAQ |
Jan 23, 09:43
Neurocrine Biosciences Cash from Investing (Quarterly): -196.70M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -2.43B |
| Masimo Corp. | 282.30M |
| Insulet Corp. | -31.00M |
| Marker Therapeutics, Inc. | 0.00 |
| CapsoVision, Inc. | -0.012M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 227.50M |
| Cash from Financing (Quarterly) | 45.60M |
| Free Cash Flow | 593.10M |
| Free Cash Flow Per Share (Quarterly) | 2.091 |
| Free Cash Flow to Equity (Quarterly) | 224.40M |
| Free Cash Flow to Firm (Quarterly) | 214.30M |
| Free Cash Flow Yield | 4.19% |